Stage I Endometrial Cancer

• Stage I Endometrial Cancer is cancer confined to the uterus, specifically the endometrium and potentially the myometrium.
• Abnormal vaginal bleeding, especially postmenopausal bleeding, is the most common symptom.
• Diagnosis typically involves endometrial biopsy and imaging studies.
• Treatment primarily involves surgery, often followed by radiation therapy in some cases.
• The prognosis for Stage I Endometrial Cancer is generally favorable due to its early detection and localized nature.

What is Stage I Endometrial Cancer?

Stage I Endometrial Cancer is defined as cancer that is localized entirely within the uterus. This means the cancerous cells have not spread beyond the uterine wall to other organs or distant sites. It is further subdivided into Stage IA and Stage IB based on the depth of invasion into the myometrium (the muscular wall of the uterus).

In Stage IA, the tumor invades less than half of the myometrium, while in Stage IB, the tumor invades half or more of the myometrium. Endometrial cancer is the most common gynecologic cancer in the United States, with an estimated 66,200 new cases and 13,030 deaths in 2023, according to the American Cancer Society. The majority of cases are diagnosed at an early stage, like Stage I, which contributes to a generally good prognosis.

Symptoms and Diagnosis of Stage I Endometrial Cancer

The most common indicator of endometrial cancer, including stage 1 endometrial cancer symptoms, is abnormal vaginal bleeding. This can manifest as postmenopausal bleeding, irregular or heavy menstrual periods in premenopausal women, or bleeding between periods. Other less common symptoms might include pelvic pain or pressure, or changes in vaginal discharge. It is important for women experiencing any of these symptoms to consult a healthcare provider promptly, as early investigation can lead to timely diagnosis.

Diagnosis typically begins with a physical examination and a review of the patient’s medical history. If endometrial cancer is suspected, further diagnostic procedures are performed. These often include a transvaginal ultrasound to assess the thickness of the uterine lining, followed by an endometrial biopsy, which involves taking a small tissue sample from the uterus for microscopic examination. In some cases, a dilation and curettage (D&C) procedure may be necessary to obtain a more comprehensive tissue sample. Imaging tests like MRI or CT scans may also be used to evaluate the extent of the cancer within the uterus and to rule out spread to other areas, although Stage I implies no such spread.

Common symptoms that warrant medical attention include:

• Postmenopausal vaginal bleeding
• Unusual vaginal discharge
• Pelvic pain or cramping
• Pain during intercourse
• Changes in bowel or bladder habits (less common in Stage I)

Treatment and Prognosis for Stage I Endometrial Cancer

The primary stage 1 endometrial cancer treatment is surgery, typically a total hysterectomy (removal of the uterus and cervix) and bilateral salpingo-oophorectomy (removal of both fallopian tubes and ovaries). Lymph node dissection may also be performed to check for cancer spread, which helps in further staging and treatment planning. The extent of surgery depends on the specific characteristics of the tumor and the patient’s overall health.

Following surgery, some patients, particularly those with higher-risk features (such as deeper myometrial invasion or aggressive tumor types), may receive adjuvant therapy. This often includes radiation therapy, which can be delivered externally (external beam radiation therapy) or internally (brachytherapy), to reduce the risk of recurrence in the pelvis. Chemotherapy is generally not a primary treatment for Stage I disease but may be considered in very specific, high-risk situations.

The prognosis stage 1 endometrial cancer is generally excellent, reflecting the localized nature of the disease at diagnosis. For women with Stage I Endometrial Cancer, the 5-year survival rate is very high, often exceeding 90%. Factors influencing prognosis include the specific subtype of cancer, the depth of myometrial invasion, and the presence of lymphovascular space invasion. Regular follow-up appointments, including physical exams and symptom reviews, are crucial after treatment to monitor for any signs of recurrence and to manage potential long-term side effects.